Variations in subclinical left ventricular dysfunction, functional capacity, and clinical outcomes in different heart failure aetiologies by Wang, Y et al.
Variations in subclinical left ventricular dysfunction,
functional capacity, and clinical outcomes in different
heart failure aetiologies
Ying Wang1, Hong Yang1, Mark Nolan1, Faraz Pathan1, Kazuaki Negishi1 and Thomas H. Marwick1,2*
1Menzies Institute for Medical Research, Hobart, Australia; 2Baker Heart and Diabetes Institute, Melbourne, Australia
Abstract
Aims Patients with heart failure (HF) risk factors are described as being in Stage A of this condition (SAHF). Management is
directed towards prevention of HF progression, but to date, no evidence has been described to align the intensity of this in-
tervention to HF risk. We sought to what extent SAHF of Type 2 diabetes mellitus (T2DM) and other HF risks showed differ-
ences in subclinical left ventricular function, exercise capacity, and prognosis.
Methods and results We recruited 551 elder asymptomatic SAHF patients (age 71 ± 5 years, 49% men, 290 T2DM) with at
least one risk factor from a community-based population with preserved ejection fraction. All underwent a comprehensive
echocardiogram including global longitudinal strain (GLS) and a 6 min walk test and were followed for 2 years. The primary
endpoints were new-onset HF and all-cause mortality. The T2DM group was associated with reduced 6 min walk test distance
(451 ± 111 vs. 493 ± 87 m, P < 0.001), worse diastolic function (E/e0 9.2 ± 2.7 vs. 8.7 ± 2.4, P = 0.028), and impaired GLS
(17.7 ± 2.6% vs. 19.0 ± 2.6%, P < 0.001). Over a median follow-up of 1.6 years, 49 T2DM-SAHF and 27 other-SAHF met
the primary endpoint. T2DM-SAHF had signiﬁcantly worse outcome than other-SAHF (P = 0.021). In Cox models, obesity [haz-
ard ratio (HR) = 2.46; P = 0.007], atrial ﬁbrillation (HR = 2.39; P = 0.028), 6 min walk distance (HR = 0.99; P = 0.034), and GLS
(HR = 1.14; P = 0.033) were independently associated with the primary endpoint in T2DM-SAHF, independent of age and
glycaemic control.
Conclusions The T2DM-SAHF has worse subclinical left ventricular function, exercise capacity, and prognosis than other-
SAHF. Impaired GLS, atrial ﬁbrillation, exercise capacity, and obesity are associated with a worse prognosis in T2DM-SAHF
but not in other-SAHF.
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Introduction
The current American College of Cardiology/American Heart
Association heart failure (HF) guidelines deﬁne Stage A HF
(SAHF) as existing in subjects with risk factors for HF, in the ab-
sence of structural heart disease or symptoms.1 These risk fac-
tors include obesity, hypertension, atherosclerosis, diabetes
mellitus (DM), exposure to cardiotoxins, and family history of
HF, and they may be present in up to a third of subjects aged
≥45 years. The natural history of SAHF is that patients may
progress to functional or structural abnormalities without
symptoms [Stage B HF (SBHF)], clinical manifestations of
HF (Stage C), and eventually, refractory or end-stage HF
(Stage D).2,3 The identiﬁcation of HF risk should stimulate ef-
forts to identify SBHF, as therapeutic interventions in this set-
ting may prevent the development of clinical HF and improve
prognosis.2,3 However, an effective screening strategy necessi-
tates an understanding of underlying risk.4
A recent systematic review of the relative risk of a large
range of HF risk factors showed that Type 2 DM (T2DM)
had nearly double the risk of incident HF, while the risk with
hypertension was lower.5 The frequency of HF in patients
with DM is even higher among elderly subjects.6 The pres-
ence of T2DM adversely affects the prognosis of patients with
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HF, with contributions from coronary heart disease, diabetic
cardiomyopathy, and hypertension.7,8 Even in the absence
of ischaemic heart disease, T2DM is over-represented in
HF.9 We hypothesized that non-ischaemic SAHF due to
T2DM would have more subclinical left ventricular (LV) dys-
function and worse functional capacity and clinical outcomes,
compared with other SAHF. This ﬁnding might justify a more
aggressive stance towards screening for SBHF in T2DM.
Methods
Patient selection
We prospectively recruited 551 asymptomatic patients aged
≥65 years, with preserved ejection fraction (EF) but at least
one Stage A risk factor for HF (DM, obesity, hypertension, or
known cardiac disease), from a community-based population
in Tasmania. Patients with existing HF or known ischaemic
heart disease were excluded, as were patients with more than
moderate valve disease, history of HF, LV EF<40%, inability to
acquire adequate echocardiographic images for speckle track-
ing imaging analysis at baseline. All participants provided writ-
ten informed consent, and the study protocol was approved
by the Tasmanian Human Research Ethics Committee.
Clinical features
Type 2 DM was based on self-report of diagnosis including
medication. Obesity was deﬁned as body mass index (BMI)
≥30 kg/m2.
Demographics, disease and family history, and medication
use were obtained using a standardized questionnaire. BMI
was calculated as weight in kilograms divided by height in
metres squared. In addition to standardized weight and
height measurements, waist circumference was measured
with a tape measure to the nearest millimetre at the mid-
point between the lower costal margin and the iliac crest
by a trained examiner. Supine resting blood pressure (BP)
was measured twice and averaged in each patient after at
least 10 min of rest in a quiet room. Uncontrolled hyperten-
sion was deﬁned by averaged systolic BP ≥140 mmHg or a di-
astolic BP ≥ 90 mmHg.10 The International Federation of
Clinical Chemistry standardized haemoglobin A1c (HbA1c)
(cut-off 64 mmol/mol) level, estimated glomerular ﬁltration
rate (eGFR), and creatinine were obtained from local pathol-
ogy records. Missing values for HbA1c, eGFR, and creatinine
were estimated by imputation using linear regression.
Six-minute walk test
The 6 min walk test (6MWT) was performed by traversing
back and forth along a marked pathway on a hard, ﬂat
surface, to test the distance an individual was able to walk
over a total of 6 min. Patients were allowed to self-pace,
and the test was performed using a standardized protocol.11
Echocardiography
A comprehensive echocardiogram including standard trans-
thoracic 2D, Doppler echocardiographic studies, and speckle
tracking echocardiogram using sensitive systolic and diastolic
function parameters was performed using the same
ultrasound machine (Siemens ACUSON SC2000, 4V1c and
4Z1c probes, Siemens Healthcare, Mountain View, CA) in
accordance with the American Society of Echocardiography
guidelines.12,13 Images were saved in raw data format and
analysed ofﬂine. LV internal dimensions and wall thickness,
chamber volumes, and valvular morphology were assessed.
LV mass index was obtained from LVmass measurement using
standard criteria and normalized for body size (body surface
area or height to the power of 1.7). LV EF measurement used
themodiﬁed Simpson biplanemethod. LV inﬂowwas obtained
using pulsed wave Doppler in the apical four-chamber view;
peak early (E) and late (A) diastolic velocities, deceleration
time, and E/A ratio were assessed. Peak early diastolic medial
and lateral mitral annular velocities (e0) and the ratio of mitral
inﬂow early diastolic velocity to average e0 velocity were
obtained from pulsed tissue Doppler; E/e0 >13 was used as
an indicator of diastolic dysfunction. For deformation analysis,
standard greyscale two-dimensional images were acquired in
conventional four-chamber, two-chamber, three-chamber,
parasternal short-axis views at the mid-level, basal level, and
apical level. Global longitudinal strain (GLS) was calculated
by averaging three apical views using standard software and
greater than 18% was considered consistent with LV
dysfunction.14,15
Outcomes
Potential HF symptoms were assessed through regular
follow-up phone calls, followed by symptom surveillance
questionnaires and clinical visits. Records of all-cause hospi-
talization were obtained and collected. Suspicious HF symp-
toms and signs were reviewed by three independent
cardiologists. The diagnosis of HF was established according
to the Framingham HF criteria.16 The primary endpoint for
study was new onset of HF and all-cause mortality.
Statistical analysis
Descriptive data are presented as mean ± standard deviation,
and dichotomous data as subject number and percentage.
Comparisons between the groups were performed by
independent-samples t-test; the Kruskal–Wallis test was used
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for comparison of non-normally distributed variables.
Univariable Cox regression was used in order to identify the
predictors with the primary endpoint among clinical, demo-
graphic, and echocardiographic variables. Multivariable Cox
proportional hazards model was performed to determine
the independent predictors and reported as hazard ratio
(HR) with 95% conﬁdence interval, guided by univariable
analyses. Analyses were performed with standard statistical
computer software (SPSS 22, IBM, Chicago, IL); P < 0.05
was deemed to be statistically signiﬁcant.
Results
Patient characteristics
All 551 SAHF patients (age 71 ± 5 years, 49% male) were eligi-
ble for inclusion in the ﬁnal analysis. T2DM was present in 290
subjects (53%). The clinical and demographic characteristics
of the SAHF patients according to T2DM status are listed in
Table 1. T2DM-SAHF was characterized by more obesity as
well as central obesity, higher heart rate, and lower diastolic
BP. The 6 min walk distance (6MWD) was signiﬁcantly lower
in T2DM-SAHF patients compared with other-SAHF patients
(451 ± 111 vs. 493 ± 87 m, P< 0.001). Among T2DM-SAHF pa-
tients, 24% patients were treated with insulin and 68% with
metformin. The mean HbA1c level is 53.7 ± 10.3 mmol/mol
with 13% having impaired HbA1c level (>64 mmol/mol). For
eGFR, 14% patients had eGFR > 90 mL/min/1.73 m2, 71%
had eGFR 60–90 mL/min/1.73 m2, and 15% had
eGFR < 60 mL/min/1.73 m2. The mean creatinine value was
92 ± 21 μmol/L.
Echocardiographic characteristics
Table 2 shows the echocardiographic characteristics between
T2DM-SAHF and the remaining SAHF group. Overall, the mean
EF was 63 ± 6% (range 40–80%), and only 2% and 1% had EF
within 40–50% in T2DM-SAHF and other-SAHF patients, re-
spectively. Average GLS was 18.4 ± 2.7% (range 10.4% to
26.0%). T2DM-SAHF had higher E/e0 ratio, higher LV mass
Table 1 Demographic and clinical characteristics of the SAHF population according to T2DM status
T2DM-SAHF (n = 290) Other-SAHF (n = 261) P value
Age (years) 71 ± 4.4 71 ± 5.1 0.877
Male gender (n, %) 163 (56.2) 106 (40.6) <0.001
Weight (kg) 86.2 ± 17.1 79.7 ± 15.4 <0.001
Height (cm) 168.4 ± 9.9 166.6 ± 9.4 0.027
BMI (kg/m2) 30.4 ± 5.9 28.6 ± 4.7 <0.001
Waist circumference (cm) 103.7 ± 13.3 96.8 ± 13.7 <0.001
Obesity (n, %) 142 (49.0) 108 (41.4) 0.074
Heart rate (n/min) 69 ± 11 66 ± 11 0.001
Systolic blood pressure (mmHg) 139 ± 15 141 ± 18 0.143
Diastolic blood pressure (mmHg) 81 ± 10 83 ± 11 0.021
Hypertension (n, %) 222 (76.6) 231 (88.5) <0.001
Active hypertension (n, %) 143 (49.3) 132 (50.6) 0.767
Past heart disease (n, %) 20 (6.9) 24 (9.2) 0.321
Family history of HF (n, %) 90 (31.0) 115 (44.1) 0.002
Past chemotherapy (n, %) 24 (8.3) 25 (9.6) 0.592
Atrial ﬁbrillation (n, %) 29 (10) 18 (6.9) 0.224
6MWD (m) 451 ± 111 493 ± 87 <0.001
Biomarker
HbA1c (mmol/mol) 53.7 ± 10.3 — —
Impaired HbA1c
(>64 mmol/mol)
38 (13.1) — —
eGFR
>90 mL/min/1.73 m2 41 (14.1) — —
60–90 mL/min/1.73 m2 207 (71.4) — —
<60 mL/min/1.73 m2 42 (14.5) — —
Creatinine (μmol/L) 91.8 ± 21.4 — —
Medication
Insulin 69 (23.8) — —
Metformin 196 (67.6) — —
ACEI/ARB (n, %) 201 (69.3) 190 (72.8) 0.368
Beta-blockers (n, %) 16 (5.5) 13 (5.0) 0.778
Calcium antagonists (n, %) 68 (23.4) 68 (26.1) 0.108
Diuretics (n, %) 33 (11.4) 42 (16.1) 0.479
Lipid-lowering medications
(n, %)
148 (51.0) 149 (57.1) 0.155
ARB, angiotensin II receptor blocker; ACEI, angiotensin-converting enzyme inhibitor; BMI, body mass index; eGFR, estimated glomerular
ﬁltration rate; HbA1c, haemoglobin A1c; HF, heart failure; SAHF, Stage A heart failure; 6MWD, 6 min walk distance; T2DM, Type 2 diabe-
tes mellitus. Bold P values are signiﬁcant.
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index, and worse GLS than the other-SAHF group. The T2DM
group was associated with worse diastolic function (E/e0
9.2 ± 2.7 vs. 8.7 ± 2.4, P = 0.028) as well as impaired GLS
(17.7 ± 2.6 vs. 19.0 ± 2.6%, P < 0.001). T2DM-SAHF also
had a much higher prevalence of abnormal GLS (50% vs.
28%, P < 0.001) and abnormal E/e0 (10% vs. 5%, P = 0.011).
In order to determine the incremental impact of T2DM on
subclinical systolic and diastolic functions over hypertension,
Table 3 lists echocardiographic parameter comparisons
between patients with isolated active hypertension (HT-
SAHF) and patients with both active hypertension and
T2DM (HT + T2DM-SAHF). HT + T2DM-SAHF had worse GLS
than the HT-SAHF group. HT + T2DM-SAHF also had a much
higher prevalence of abnormal GLS (52% vs. 30%, P < 0.001).
Follow-up
Over a median follow-up period of 1.6 ± 0.6 years (range
0.6–3.2 years), 49 (16.9%) T2DM-SAHF and 27 (10.3%)
other-SAHF met the primary endpoint of new onset of
HF and all-cause mortality. On examination of individual com-
ponents of the primary endpoint, 46 T2DM-SAHF and 24
other-SAHF developed HF, and three T2DM-SAHF and three
other-SAHF died. In the entire cohort, the annualized event
rate of HF and all-cause mortality was 8.8%—varying from
11.2% in T2DM-SAHF to 6.4% in other-SAHF.
Stepwise nested Cox models were constructed to deter-
mine the predictors of primary outcome in SAHF patients
with and without T2DM. HRs of the primary outcome from
univariable and multivariable analyses are listed in Table 4.
Signiﬁcant variables from univariable analyses were entered
into the ﬁnal age-adjusted and sex-adjusted model. Among
T2DM-SAHF patients, obesity [HR = 2.46 (1.28 to 4.70);
P = 0.007], atrial ﬁbrillation (AF) [HR = 2.39 (1.10 to 5.22);
P = 0.028], 6MWD [HR = 0.99 (0.99 to 1.00); P = 0.034], and
GLS [HR = 1.14 (1.01 to 1.30); P = 0.033] were independently
associated with the primary endpoint after adjustment for
age, gender, and glycaemic control. In the other-SAHF cohort,
history of heart disease [HR = 2.97 (1.19 to 7.4); P = 0.019]
was predictive after adjustment for age [HR = 1.08 (1.01 to
1.15); P = 0.022] and gender.
Table 3 Echocardiographic characteristics of the SAHF population according to T2DM and hypertension status
HT-SAHFa (n = 132) HT + T2DM-SAHFb (n = 143) P value
LV ejection fraction (%) 63.6 ± 5.6 62.7 ± 6.9 0.247
Mitral early-diastolic inﬂow velocity (E wave) (m/s) 0.61 ± 0.15 0.67 ± 0.17 0.008
Mitral late diastolic inﬂow velocity (A wave) (m/s) 0.80 ± 0.16 0.85 ± 0.20 0.016
Early-to-late peak diastolic transmitral ﬂow velocity ratio (E/A) 0.78 ± 0.19 0.79 ± 0.23 0.513
Early diastolic mitral annular velocity (e0) (m/s) 0.07 ± 0.02 0.08 ± 0.02 0.220
Mitral E/e0 septal–lateral ratio (E/e0) 9.0 ± 2.5 9.4 ± 2.8 0.185
E/e0 ratio > 13 (n, %) 8 (6.1) 18 (12.6) 0.065
Deceleration time (s) 247.5 ± 49.7 246.5 ± 52.1 0.882
LV mass index (g/m2) 93.4 ± 21.5 95.1 ± 25.1 0.547
LVH/LV mass index 41 (31.1) 44 (30.8) 0.989
GLS (%) 19.1 ± 2.4 17.7 ± 2.5 <0.001
GLS > 18% (n, %) 39 (29.5) 74 (51.7) <0.001
GLS, global longitudinal strain; HT, hypertension; LV, left ventricular; LVH, left ventricular hypertrophy; SAHF, Stage A heart failure; T2DM,
Type 2 diabetes mellitus. Bold P values are signiﬁcant.
aHT-SAHF: Patients had active hypertension without diabetes.
bPatients had both T2DM and active hypertension.
Table 2 Echocardiographic characteristics of the SAHF population according to T2DM status
T2DM-SAHF (n = 290) Other-SAHF (n = 261) P value
LV ejection fraction (%) 62.9 ± 6.5 63.9 ± 5.5 0.048
40–50% 5 (1.7) 3 (1.1)
>50% 285 (98.3) 258 (98.9)
Mitral early diastolic inﬂow velocity (E wave) (m/s) 0.65 ± 0.17 0.63 ± 0.15 0.057
Mitral late diastolic inﬂow velocity (A wave) (m/s) 0.83 ± 0.19 0.78 ± 0.17 0.001
Early-to-late peak diastolic transmitral ﬂow velocity ratio (E/A) 0.80 ± 0.21 0.82 ± 0.23 0.167
Early diastolic mitral annular velocity (e0) (m/s) 0.08 ± 0.02 0.08 ± 0.02 0.306
Mitral E/e0 septal–lateral ratio (E/e0) 9.2 ± 2.7 8.7 ± 2.4 0.028
E/e0 ratio > 13 (n, %) 30 (10.3) 12 (4.6) 0.011
Deceleration time (s) 246.4 ± 52.4 242.8 ± 49.4 0.414
LV mass index (g/m2) 92.4 ± 23.8 92.7 ± 22.1 0.912
LVH/LV mass index 167 (57.6) 179 (68.6) 0.009
GLS (%) 17.7 ± 2.6 19.0 ± 2.6 <0.001
GLS > 18% (n, %) 146 (50.3) 74 (28.4) <0.001
GLS, global longitudinal strain; LV, left ventricular; LVH, left ventricular hypertrophy; SAHF, Stage A heart failure; T2DM, Type 2 diabetes
mellitus. Bold P values are signiﬁcant.
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Kaplan–Meier survival curves were constructed for the pri-
mary endpoint, with log-rank testing for signiﬁcance between
strata. Among the whole cohort, T2DM-SAHF had signiﬁcantly
worse outcome than other-SAHF (χ2 = 5.36; P = 0.021;
Figure 1). Subclinical LV systolic dysfunction (LVSD) (deﬁned
as GLS > 18%) was predictive of primary outcome (HF
and all-cause mortality) in T2DM-SAHF in Kaplan–Meier anal-
ysis (χ2 = 6.75; P = 0.009; Figure 2A). However, there was no
statistically signiﬁcant difference in survival when comparing
other-SAHF with or without LVSD (χ2 = 2.68; P = 0.101;
Figure 2B). There were signiﬁcantly more events in T2DM-
SAHF with obesity compared with those without
(χ2 = 11.86; P = 0.001; Figure 3A), but there were no differ-
ences when other-SAHF was divided by obesity (χ2 = 0.09;
P = 0.770; Figure 3B). In T2DM-SAHF patients, the most seri-
ous prognosis pertained to those with impaired GLS or obe-
sity. However, as shown in Figure 4, in other-SAHF
individuals, the most serious prognosis was seen in those
with a history of heart disease (χ2 = 12.49; P < 0.001).
Discussion
In these data from a prospectively enrolled cohort, we exam-
ined the prevalence of subclinical LV dysfunction, impaired
exercise capacity, and prognosis in a community-based popu-
lation with HF risk factors. The results suggest that SAHF due
to T2DM has a worse echocardiographic manifestation,
functional capacity, and clinical outcome than other-SAHF.
This work builds on previous reports of an association be-
tween increasing HF stage and worse functional status and
prognosis,17 by adding evidence about clinical features and
functional capacity within the early asymptomatic phases of
HF.
Left ventricular mechanics in Stage A heart failure
Previous studies have shown that changes of subclinical LV
longitudinal systolic and diastolic function begin before struc-
tural LV changes in asymptomatic patients with HF risk fac-
tors.18–21 However, comparisons of the degree of LV
myocardial dysfunction in early diabetic cardiomyopathy
and in other-SAHF have not been documented previously.
Our results show that abnormalities of diastolic function are
more common in T2DM than in other-SAHF groups, as are
disturbances of LV longitudinal systolic function (GLS:
17.7 ± 2.6% vs. 19.0 ± 2.6%, P < 0.001). In the current
study, we report that the prevalence of systolic longitudinal
dysfunction is 50% among community population-based
T2DM-SAHF and 28% among other-SAHF. Alterations of sys-
tolic strain may exist despite normal diastolic function.22 Im-
portantly, impaired GLS as a marker of SBHF is associated
with an increased risk of further transition to symptomatic
Stage C HF with preserved EF in diabetes.2 However, in real
life, few asymptomatic SAHF patients undergo tests of car-
diac morphology and function, and perhaps because of this,
Figure 1 Comparison of primary outcomes between patients with T2DM-SAHF and other-SAHF. SAHF patients with T2DM had signiﬁcantly worse out-
come than those without T2DM. SAHF, Stage A heart failure; T2DM, Type 2 diabetes mellitus.
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many of them develop into Stage C/D directly without
experiencing SBHF. Effectively, many SBHF ‘hide’ in SAHF,
and our results highlight the importance of echocardiography
for identifying SBHF and initiating cardioprotection.
These ﬁndings highlight the fact that the severity of the
early LV function impairment is not necessarily analogous
within different aetiologies of SAHF. Despite rigorous
adjustment for covariables, each unit decrement of GLS in
subjects with T2DM showed a 1.14-fold higher risk of HF
and mortality, whereas in subjects with other risks, the pre-
dictive value of GLS was not found. The worse LV function
in T2DM-SAHF may be attributable to diabetic complications
and associated co-morbidities as well as the presence of a
distinct diabetic cardiomyopathy.4,18 The pathogenesis of
Figure 2 Prognostic implications of T2MD-SAHF and other-SAHF and the role of left ventricular systolic dysfunction. SAHF, Stage A heart failure; T2DM,
Type 2 diabetes mellitus.
(A)
(B)
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the latter is complex and likely multifactorial, involving car-
diac autonomic neuropathy, altered myocardial metabolism,
small-vessel and large-vessel damage, insulin resistance, and
myocardial ﬁbrosis.18 Additionally, in our study, patients with
uncontrolled hypertension showed relatively preserved GLS,
but a combined group with active hypertension and T2DM
had more abnormal GLS (19.1 ± 2.4% vs. 17.7 ± 2.5%,
P < 0.001; Table 3), as well as a higher prevalence of abnor-
mal GLS than in T2DM without hypertension (52% vs. 30%).
Although hypertension and T2DM are the two leading aetiol-
ogies of early HF, impaired GLS is more likely due to diabetic
cardiomyopathy than hypertensive heart disease.23
Functional capacity in Stage A heart failure
In this study, functional capacity at submaximal stress was
assessed using 6MWT. This is a simple, safe test of functional
Figure 3 Prognostic implications of T2MD-SAHF and other-SAHF and the role of obesity. SAHF, Stage A heart failure; T2DM, Type 2 diabetes mellitus.
(A)
(B)
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capacity that is a well-established diagnostic procedure in
cardiovascular and pulmonary disease, which has prognostic
value.24 A systematic review25 to investigate the reliability
between 6MWT and other methods to assess functional ca-
pacity showed that 6MWT has moderate to good ability to
predict VO2 in chronic HF, especially in those patients who
are unable to walk >490 m. Compared with healthy controls,
patients with T2DM have lower 6MWD.26 The results of this
study show that, compared with that in other-SAHF, func-
tional capacity in T2DM-SAHF was more impaired.
The determinants of functional capacity are complex and
depend on both psychological and physical factors. Although
Figure 4 Prognostic implications of T2MD-SAHF and other-SAHF and the role of heart disease history. SAHF, Stage A heart failure; T2DM, Type 2 di-
abetes mellitus.
(A)
(B)
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it might be considered that the association of T2DM with
functional capacity could be driven by obesity—and indeed,
advanced age and obesity had strong associations with func-
tional capacity—our results suggest that the association of
T2DM with functional capacity was independent of these fea-
tures. Subclinical cardiac dysfunction, which is often present
in both T2DM-SAHF and other-SAHF, could inﬂuence func-
tional capacity but cannot fully explain the difference of exer-
cise capacity between the two SAHF subgroups. Previous
work has shown that exercise intolerance in T2DM is inde-
pendent of obesity and even presents with good glycaemic
control and without clinically apparent cardiovascular dis-
ease.27 The presence of endothelial dysfunction, decreased
myocardial perfusion, decreased muscle mitochondrial func-
tion, abnormal tissue haemoglobin oxygen saturation, and in-
sulin resistance may be mediators in the relationship
between diabetic oxidative dysfunction and defects in func-
tional capacity.27 In addition, there is evidence of involve-
ment of both cardiac sympathetic and cardiac
parasympathetic nervous system dysfunctions.28 Parasympa-
thetic control may be weakened by persistent
hyperglycaemia, with relative enhancement of sympathetic
activity.29 The association of heart rate recovery with vagal
tone leads to T2DM being associated with poor heart rate re-
covery and chronotropic incompetence.30 Cardiac autonomic
dysfunction is associated with reduced cardiac output re-
sponse to functional capacity in diabetes, which is probably
due to haemodynamic instability during exercise.31 Left atrial
(LA) dysfunction is also common in patients with HF with pre-
served EF and asymptomatic T2DM and contributes to exer-
cise intolerance. However, while LA enlargement in diabetes
is an independent predictor of LA dysfunction, probably ow-
ing to a combination of diastolic dysfunction and diabetic
atrial myopathy,32 the speciﬁc inﬂuence of diabetes on LA
dysfunction is more controversial.
Determinants of prognosis in Stage A heart failure
Despite current epidemiological evidence of the greater risk of
development of HF in patients with diabetes, the natural his-
tory of asymptomatic subjects at risk of HF remains poorly
identiﬁed.33,34 This study extends present knowledge about
the prognosis of the entire SAHF cohort in 2 years, based on
a community (as opposed to a clinic-based) population. In
the entire SAHF cohort, the annualized event rate of incident
HF and all-cause mortality was 8.8%. The rate in T2DM-SAHF
(11.2%) was almost twice that of other-SAHF (6.4%).
Type 2 DM was associated with more serious outcome,
irrespective of whether or not other risk factors were pres-
ent. A recent systematic review of 15 observational studies
indicated that diabetes (HR = 2.0) showed the strongest
predictive value for incident HF among the non-ischaemic
SAHF risks, followed by hypertension (HR = 1.61) and BMI
(per 5 kg/m2) (HR = 1.15).5 In the present study, the prognosis
was associated with obesity, exercise capacity, and abnormal
GLS independent of glycaemic control and renal function.
However, while hyperglycaemia may be associated with the
development of HF, the association between intensive
glycaemic control and the reduction of cardiovascular compli-
cations remains controversial.35 Although a large cohort
study reported an HbA1c ≥10% was associated with 1.6-fold
risk of incident HF relative to an HbA1c <7%, several large
clinical trials have reported no signiﬁcant beneﬁt for primary
cardiovascular events with intensive glycaemic control.35 Our
ﬁndings do not show that poor glycaemic control
(HbA1c > 64 mmol/mol) is a marker of the composite
endpoint (HF and all-cause death) in this elderly asymptom-
atic cohort.
Previous research showed that reduced eGFR is a risk
factor of cardiovascular events and death in diabetes patients
without advanced renal disease, but the risks are small when
considering other risk factors.36 Although we found no asso-
ciation between renal impairment and outcomes in T2DM-
SAHF, such an association might become apparent with
longer follow-up.
A recent systematic review and meta-analysis of 15 cohort
studies conﬁrmed the association of AF with myocardial in-
farction, HF, and all-cause mortality.37 In our study, AF
showed an independent association with increased risk of
new-onset HF and all-cause mortality in T2DM-SAHF but not
in other-SAHF. This inconsistent result in other-SHAF may
be due to the relatively low prevalence of AF (7%) and the
exclusion of ischaemic heart disease at baseline.
The staging system serves as a reminder to clinicians of the
importance of early detection and prevention of patients at
risks of transitioning to higher stages of HF. In the absence
of screening, many SAHF patients (i.e. patients with HF risk
factors) have structural or functional abnormalities that that
are unrecognized. However, echo screening in SAHF is
currently not supported by guidelines or payers, and if these
patients had not been recruited to this trial, they would have
been indistinguishable from those without any echo abnor-
malities (i.e. ‘pure’ SAHF). Nonetheless, these results highlight
the notion that SAHF associated with diabetes is clinically
different from other causes of SAHF and perhaps should have
different targets for prevention. These ﬁndings have impor-
tant implications for awareness and identiﬁcation of high-risk
individuals and optimal management to prevent or delay pro-
gression to adverse outcome in SAHF.
Limitation
Several limitations are pertinent to this study. First, the pop-
ulation for the present study was a selected group, based on
the presence of at least one known non-ischaemic HF risk fac-
tor and excluding patients with known HF or established
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asymptomatic LVSD. In addition, the prevalence of T2DM is
relatively high in this SAHF population, as we preferentially
recruited patients with diabetes by speciﬁc advertising to this
population. Second, patients with Type 1 DM were excluded
from our study, as the frequency and mechanism of cardiac
involvement may not be the same as in T2DM. Third, we
chose longitudinal strain as the most robust of the myocardial
deformation parameters and did not record circumferential
strain, which could have provided additional details about
myocardial mechanics. Finally, we do not have data on bio-
markers, which may also be used as a potential predictor of
HF and adverse outcome.
Conclusion
In this community cohort of patients with HF risks, T2DM-
SAHF had worse subclinical LV function, functional capacity,
and adverse outcome than other causes of SAHF. Impaired
GLS, worse exercise capacity, and the presence of obesity or
AF were independently associated with prognosis in T2MD-
SAHF, whereas a history of heart disease was the driver of
subsequent HF and mortality in other causes of SAHF. The
clinical application of this study provides an important caveat
that not all types of SAHF are the same. Better targeting of
interventions at the most vulnerable SAHF group—those with
T2DM—seems appropriate.
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